For instance, the response rate for melanoma patients treated with pembrolizumab (anti-PD-1) was only 33%, and also about 20–30% of patients with lung carcinoma mainly experienced desired outcomes upon ICIs blockade therapy [30]. Here, PDCD1 is linked to melanoma.